Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates
Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.
You may also be interested in...
The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.
Teva has conducted due diligence on 36 biosimilar companies with the aim of signing a partner soon to fill a critical gap in its generics pipeline.
Teva said the deal will close the first week of August, after agreeing to sell assets related to 79 pharmaceutical products to gain FTC clearance.